Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients

[1] Izumi N(1999)Global surveillance and control of hepatitis C J Viral Hepat. 6 35-47

[2] Nishiguchi S(2010)Management of hepatitis C: report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology Hepatol Res. 40 347-368

[3] Hino K(2002)Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-982

[4] Suzuki F(2006)Peginterferon and ribavirin for chronic hepatitis C N Engl J Med 355 2444-2451

[5] Kumada H(2004)Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut. 53 425-430

[6] Itoh Y(2009)Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 580-593

[7] Fried MW(2010)Randomized study of peginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C Gastroenterology 138 108-115

[8] Shiffman ML(2010)Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection Gastroenterology 138 116-122

[9] Reddy KR(1996)An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology. 24 289-293

[10] Smith C(2005)Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab. 288 462-468

[1] Izumi N(1999)Global surveillance and control of hepatitis C J Viral Hepat. 6 35-47

[2] Nishiguchi S(2010)Management of hepatitis C: report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology Hepatol Res. 40 347-368

[3] Hino K(2002)Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-982

[4] Suzuki F(2006)Peginterferon and ribavirin for chronic hepatitis C N Engl J Med 355 2444-2451

[5] Kumada H(2004)Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut. 53 425-430

[6] Itoh Y(2009)Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 580-593

[7] Fried MW(2010)Randomized study of peginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C Gastroenterology 138 108-115

[8] Shiffman ML(2010)Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection Gastroenterology 138 116-122

[9] Reddy KR(1996)An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology. 24 289-293

[10] Smith C(2005)Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab. 288 462-468